Modifications of the main hepatovirologic data induced by rituximab therapy in the 6 patients with decompensated cirrhosis
| Treatment phases . | Total protein, g/dL . | Albumin, g/dL . | ALT, IU/L . | HCV RNA, IU/mL ×103 . | Prothrombin activity, % . | Child-Pugh class . |
|---|---|---|---|---|---|---|
| Patient no. 4 | ||||||
| Before RTX infusion | 6.5 | 2.52 | 46 | 350 | 64 | C11 |
| End of treatment | 6.6 | 2.95 | 65 | 835 | 78 | B8 |
| 3rd month PTFU | 6 | 3.1 | 20 | ND | 71 | B7 |
| 6th month PTFU | 6 | 3.1 | 61 | 650 | 80 | B7 |
| Patient no. 5 | ||||||
| Before RTX infusion | 6 | 3.45 | 193 | 451 | 79 | B7 |
| End of treatment | 7.1 | 4.13 | 132 | 450 | 88 | A6 |
| 3rd month PTFU | 6.9 | 3.9 | 180 | 1100 | 82 | A5 |
| 6th month PTFU | 7.1 | 4 | 105 | 1100 | 74 | A6 |
| Patient no. 7 | ||||||
| Before RTX infusion | 7.3 | 3.4 | 153 | 14 100 | 67 | B7 |
| End of treatment | 5.9 | 3.6 | 70 | 4700 | 65 | B7 |
| 3rd month PTFU | 5.7 | 3.6 | 82 | ND | 64 | B7 |
| 6th month PTFU | 5.8 | 3.9 | 46 | ND | 59 | B7 |
| Patient no. 8 | ||||||
| Before RTX infusion | 5.3 | 3.18 | 55 | 575 | 73 | B8 |
| End of treatment | 6.3 | 3.53 | 72 | 950 | 100 | B7 |
| 3rd month PTFU | 6.8 | 3.9 | 31 | ND | 100 | A5 |
| 6th month PTFU | 6.9 | 4.03 | 131 | 750 | 100 | A6 |
| Patient no. 14 | ||||||
| Before RTX infusion | 7.1 | 3.98 | 77 | 691 | 50 | B9 |
| End of treatment | 7.3 | 3.84 | 55 | 597 | 68 | A6 |
| 3rd month PTFU | 6.8 | 3.4 | 68 | 872 | 55 | B7 |
| 6th month PTFU | 6.8 | 3.35 | 62 | 891 | 54 | B7 |
| Patient no. 15 | ||||||
| Before RTX infusion | 5.1 | 2.92 | 20 | 650 | 83.3 | B9 |
| End of treatment | 6.7 | 3.01 | 18 | 800 | 78.2 | B8 |
| 3rd month PTFU | 6.7 | 3.5 | 14 | ND | 63.5 | B8 |
| 6th month PTFU | 6.7 | 3.13 | 15 | 720 | 72.67 | B7 |
| Treatment phases . | Total protein, g/dL . | Albumin, g/dL . | ALT, IU/L . | HCV RNA, IU/mL ×103 . | Prothrombin activity, % . | Child-Pugh class . |
|---|---|---|---|---|---|---|
| Patient no. 4 | ||||||
| Before RTX infusion | 6.5 | 2.52 | 46 | 350 | 64 | C11 |
| End of treatment | 6.6 | 2.95 | 65 | 835 | 78 | B8 |
| 3rd month PTFU | 6 | 3.1 | 20 | ND | 71 | B7 |
| 6th month PTFU | 6 | 3.1 | 61 | 650 | 80 | B7 |
| Patient no. 5 | ||||||
| Before RTX infusion | 6 | 3.45 | 193 | 451 | 79 | B7 |
| End of treatment | 7.1 | 4.13 | 132 | 450 | 88 | A6 |
| 3rd month PTFU | 6.9 | 3.9 | 180 | 1100 | 82 | A5 |
| 6th month PTFU | 7.1 | 4 | 105 | 1100 | 74 | A6 |
| Patient no. 7 | ||||||
| Before RTX infusion | 7.3 | 3.4 | 153 | 14 100 | 67 | B7 |
| End of treatment | 5.9 | 3.6 | 70 | 4700 | 65 | B7 |
| 3rd month PTFU | 5.7 | 3.6 | 82 | ND | 64 | B7 |
| 6th month PTFU | 5.8 | 3.9 | 46 | ND | 59 | B7 |
| Patient no. 8 | ||||||
| Before RTX infusion | 5.3 | 3.18 | 55 | 575 | 73 | B8 |
| End of treatment | 6.3 | 3.53 | 72 | 950 | 100 | B7 |
| 3rd month PTFU | 6.8 | 3.9 | 31 | ND | 100 | A5 |
| 6th month PTFU | 6.9 | 4.03 | 131 | 750 | 100 | A6 |
| Patient no. 14 | ||||||
| Before RTX infusion | 7.1 | 3.98 | 77 | 691 | 50 | B9 |
| End of treatment | 7.3 | 3.84 | 55 | 597 | 68 | A6 |
| 3rd month PTFU | 6.8 | 3.4 | 68 | 872 | 55 | B7 |
| 6th month PTFU | 6.8 | 3.35 | 62 | 891 | 54 | B7 |
| Patient no. 15 | ||||||
| Before RTX infusion | 5.1 | 2.92 | 20 | 650 | 83.3 | B9 |
| End of treatment | 6.7 | 3.01 | 18 | 800 | 78.2 | B8 |
| 3rd month PTFU | 6.7 | 3.5 | 14 | ND | 63.5 | B8 |
| 6th month PTFU | 6.7 | 3.13 | 15 | 720 | 72.67 | B7 |
ALT indicates alanine aminotransferase; ND, not determined; and RTX, rituximab; and PTFU, posttherapy follow-up.